Prasugrel Advisory Committee Highlights FDA’s Continued Credibility Gap

Controversy over a left-out member of the advisory committee for Lilly/Daiichi Sankyo's platelet inhibitor prasugrel illustrates the challenges that FDA continues to experience in ensuring the credibility of high-profile drug reviews